An analysis conducted by PricewaterhouseCoopers shows overall implantable device operating profit declined from 2010 to 2011, suggesting the industry segment may no longer be king in the medical device market. PwC analysts measured the operating performance index for companies in in vitro diagnostics, medical consumables, medical equipment, implantable devices and diversified life sciences. Companies analyzed in the implantable devices segment included Biomet, Zimmer, Smith & Nephew, Medtronic and Integra Lifesciences.
From 2005 to 2010, the implantable device segment boasted the greatest operating profit. However, the trend reversed for the first time from 2010 to 2011. In addition, this segment saw the slowest growth in the operating performance index from 2005 to 2011.
"This advantage is declining, however, likely due to the maturation of the cardiology and orthopedic implant markets (both of which have been characterized by low growth and reimbursement challenges) and changes in purchasing dynamics and buyer behavior," the analysts wrote.
Other challenges include SG&A expenses and inventory turns. Analysts offered four strategies to improve operating performance at medical device companies:
• Broaden innovation.
• Move up the productivity curve.
• Transform the go-to market model.
• Revitalize growth strategies.
From 2005 to 2010, the implantable device segment boasted the greatest operating profit. However, the trend reversed for the first time from 2010 to 2011. In addition, this segment saw the slowest growth in the operating performance index from 2005 to 2011.
"This advantage is declining, however, likely due to the maturation of the cardiology and orthopedic implant markets (both of which have been characterized by low growth and reimbursement challenges) and changes in purchasing dynamics and buyer behavior," the analysts wrote.
Other challenges include SG&A expenses and inventory turns. Analysts offered four strategies to improve operating performance at medical device companies:
• Broaden innovation.
• Move up the productivity curve.
• Transform the go-to market model.
• Revitalize growth strategies.
More Articles on Orthopedic Devices:
Johnson & Johnson Expands in Puerto Rico
NuVasive's President of Global Sales Resigns
China, India Revamp Regulations for Medical Device Companies